Science Explorer Back to mapMap
Institution · Bakersfield College

Most cited papers from Bakersfield College

What are the most cited papers from Bakersfield College?

The most cited paper from Bakersfield College is "Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa" (Alexa B. Kimball et al., 2016), with 804 citations. Next come "Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)" (485) and "Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection" (447).

Showing 50 of 60 papers. Every paper with more than 24 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa Alexa B. Kimball et al. · New England Journal of Medicine 3 Aug 2016 804
2 Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) Carle F. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology Open access 11 Sep 2015 485
3 Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection Stefan Zeuzem et al. · New England Journal of Medicine Open access 25 Jan 2018 447
4 Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial Xavier Forns, Samuel S. Lee, Joaquin M. Valdes et al. · The Lancet Infectious Diseases 15 Aug 2017 348
5 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis Paul Yien Kwo et al. · Journal of Hepatology Open access 13 Apr 2017 302
6 Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Christopher John Edwards, Francisco Javier Blanco, Jeffrey Crowley et al. · Annals of the Rheumatic Diseases Open access 20 Jan 2016 287
7 Brief Report Sharon Lynn Walmsley, Axel Baumgarten, Juan Berenguer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access 11 Aug 2015 226
8 Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment Fred F Poordad, Franco Felizarta, Armen Asatryan et al. · Hepatology Open access 27 Jan 2017 203
9 Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) Jeffrey Crowley, Diamant Thaçi, P. Joly et al. · Journal of the American Academy of Dermatology Open access 14 Apr 2017 193
10 Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2) Eric Lawitz, Gary Matusow, Edwin DeJesus et al. · Hepatology Open access 24 Dec 2015 180
11 Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2) Phoebe A. Rich, Melinda Gooderham, Hervé Bachelez et al. · Journal of the American Academy of Dermatology Open access 10 Nov 2015 171
12 Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial Robert S. Brown et al. · Journal of Hepatology Open access 2 Nov 2019 157
13 Calibrating Environmental DNA Metabarcoding to Conventional Surveys for Measuring Fish Species Richness Mary E. McElroy, Terra L. Dressler, Georgia Titcomb et al. · Frontiers in Ecology and Evolution Open access 28 Aug 2020 155
14 Early Tertiary sedimentation in the western Uinta Basin, Utah Robert T. Ryder, Thomas D. Fouch, JAMES H. ELISON · Geological Society of America Bulletin 1976 148
15 Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial David L. Wyles, Fred F Poordad, Stanley Wang et al. · Hepatology Open access 19 Sep 2017 147
16 Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Bruce E Strober, Jeffrey Crowley, Paul Steven Yamauchi et al. · British Journal of Dermatology 17 May 2011 146
17 Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure Fred F Poordad, Stanislas Pol, Armen Asatryan et al. · Hepatology Open access 20 Nov 2017 140
18 Transcriptional Orchestration of the Global Cellular Response of a Model Pennate Diatom to Diel Light Cycling under Iron Limitation Sarah R. Smith, Jeroen Gillard, Adam B. Kustka et al. · PLoS Genetics Open access 14 Dec 2016 136
19 Lectures on the Scientific Basis of Medicine Robert Warren Huntington · American Journal of Clinical Pathology Sep 1956 132
20 Involuntary inferior and multidirectional instability of the shoulder: etiology, recognition, and treatment. J H VARNEY, J K COKER, J J CAWLEY · PubMed 1952 132
21 Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine Jacob Paul Lalezari, J. Greg Sullivan, Peter Varunok et al. · Journal of Hepatology Open access 5 Apr 2015 119
22 Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy Kim Alexander Papp, Jeffrey Crowley, J.‐P. Ortonne et al. · British Journal of Dermatology 16 Nov 2010 117
23 Treatment of Nail Psoriasis Jeffrey Crowley, Jeffrey M Weinberg, Jashin J. Wu et al. · JAMA Dermatology 4 Dec 2014 100
24 Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni Elizabeth Elewski, Martin M. Okun, Kim Alexander Papp et al. · Journal of the American Academy of Dermatology Open access 12 Oct 2017 87
25 Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis Jeffrey Crowley, Richard Bruce Warren, Jennifer Cather · Journal of the European Academy of Dermatology and Venereology Open access 6 May 2019 85
26 Characterization of a Two-Component System Transcriptional Regulator, LtdR, That Impacts Group B Streptococcal Colonization and Disease Liwen Deng, Rong Mu, Thomas A. Weston et al. · Infection and Immunity Open access 23 Apr 2018 82
27 One size does not fit all: Toward regional conservation practice guidance to reduce phosphorus loss risk in the Lake Erie watershed Merrin L. Macrae, Helen P. Jarvie, Roy Brouwer et al. · Journal of Environmental Quality Open access 20 Mar 2021 79
28 Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities Jeffrey Crowley, Jan R. Mekkes, Christos C. Zouboulis et al. · British Journal of Dermatology Open access 19 May 2014 78
29 Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis Jennifer Clay Cather, Jeffrey Crowley · American Journal of Clinical Dermatology Open access 5 Nov 2014 64
30 Load-deflection characteristics of nickel-titanium alloy wires after clinical recycling and dry heat sterilization Sunil Kapila, John W. Haugen, L.G. Watanabe · American Journal of Orthodontics and Dentofacial Orthopedics Aug 1992 59
31 Improving Placement Accuracy in California’s Community Colleges Using Multiple Measures of High School Achievement Peter Riley Bahr, Loris P. Fagioli, John J. Hetts et al. · Community College Review Open access Apr 2019 56
32 Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study C. Leonardi, Jeffrey M. Sobell, Jeffrey Crowley et al. · British Journal of Dermatology 7 May 2012 52
33 Classification of central amazon lakes on the basis of their microbiological and physico-chemical characteristics Hakugiat Rai, Gary Hill · Hydrobiologia Jul 1980 51
34 The Relational Turbulence Model: A Meta-Analytic Review Alan K. Goodboy, San Bolkan, Liesel L. Sharabi et al. · Human Communication Research Apr 2020 46
35 Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial Boni Elizabeth Elewski, Christopher Baker, Jeffrey Crowley et al. · Journal of the European Academy of Dermatology and Venereology Open access 15 Jul 2019 45
36 The Diving and Feeding Activity of the Western Grebe on the Breeding Grounds George E. Lawrence · Ornithological Applications 1950 45
37 Impact of Entomopathogenic Fungi on the Growth, Development, and Health of Cabbage Growing under Water Stress Surendra K. Dara, Sumanth S. R. Dara, Suchitra S. Dara · American Journal of Plant Sciences Open access 2017 42
38 Efficacy of adalimumab across subgroups of patients with moderate‐to‐severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH Yves P. Poulin, Jeffrey Crowley, Richard G B Langley et al. · Journal of the European Academy of Dermatology and Venereology Open access 22 Jun 2013 42
39 ?-Lipoic acid-based PPAR? agonists for treating inflammatory skin diseases MeenakshiS. Venkatraman, Amar Gopal Chittiboyina, Josef G. Meingassner et al. · Archives of Dermatological Research 23 Jun 2004 41
40 Growth Hormone Alters Brain Morphometry, Connectivity, and Behavior in Subjects with Fatigue after Mild Traumatic Brain Injury Traver J. Wright, Randall J. Urban, William Durham et al. · Journal of Neurotrauma Open access 4 Dec 2019 40
41 Selecting Optimum Planting Dates and Plant Populations for Dryland Corn in Kansas Scott Staggenborg, D. L. Fjell, Daniel L. Devlin et al. · jpa 1999 39
42 Fumigating `Crimson Seedless' Table Grapes with (E)-2-Hexenal Reduces Mold during Long-term Postharvest Storage Douglas D. Archbold, Thomas R. Hamilton–Kemp, Ann M. Clements et al. · HortScience Open access Jul 1999 38
43 An Acute Pulmonary Coccidioidomycosis Coinfection in a Patient Presenting With Multifocal Pneumonia With COVID-19 Cameron Casey Chang, Randolph Senining, Jessica Kim et al. · Journal of Investigative Medicine High Impact Case Reports Open access 2020 37
44 Functional iron deficiency in hemodialysis patients with high ferritin Robert C. Kopelman, Lorelei SMITH, Leonard PEOPLES et al. · Hemodialysis International 31 Mar 2007 37
45 DNA barcoding exposes a case of mistaken identity in the fern horticultural trade Kathleen M. Pryer, Eric Schuettpelz, Layne Huiet et al. · Molecular Ecology Resources 9 Apr 2010 36
46 Racism‐Related Stress, General Life Stress, and Psychological Functioning Among Black American Women Alex L. Pieterse, Robert T. Carter, Kilynda V. Ray · Journal of Multicultural Counseling and Development 2013 36
47 Scalp psoriasis: an overview of the disease and available therapies. Jeffrey Crowley · PubMed Aug 2010 36
48 Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy Jason Grebely, Gregory J. Dore, Negar Niki Alami et al. · International Journal of Drug Policy Open access 5 Feb 2019 35
49 Proceedings of the Symposium on Coccidioidomycosis Robert Warren Huntington · American Journal of Clinical Pathology Oct 1959 33
50 Mouth-to-mouth ventilation: The dying art Anthony Don Michael, James S. Forrester · The American Journal of Emergency Medicine Mar 1992 30

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.